Trial Profile
A study investigating fusion products after crizotinib treatment in crizotinib resistant patients with lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2015
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Lung cancer
- Focus Pharmacodynamics
- 24 Aug 2015 New trial record